In a cancer trial, the combination of anti-CTLA4 with placebo resulted in a 31% risk reduction in overall mortality, with 20% of patients alive at 56 months in the treatment group compared to nearly 0% in the placebo group.

“what you'll notice is that in the top you're looking at um um sort of uh it's it's comparing the antict 4 with GP100 versus the gp1 100 and in the bottom you're looking at the anti ca4 versus the GP 100 so at a glance you can see GP 100 is not doing anything I mean that's the that's the first takeaway of comparing A to B um what I find most interesting is look at the subgroup analysis of females notice that in females while there's a trend towards risk reduction and this is risk reduction for overall mortality so again I just want to restate that the primary outcome of this trial was changed to overall survival which I think is the better outcome by the way and overall for all patients in when you compare antict 4 plus Placebo versus placebo there was a 31% risk reduction in overall mortality”